Barcelona, February 27, 2026 – Catalonia.health participated this week in the fourth edition of the "Next Health: Life Sciences Innovation" conference series, co-organised with EY, focused on analysing how the Health & Life Sciences sector is generating tangible impact in sustainability. The event brought together experts from leading companies to share concrete examples of transformation and advances in this strategic area.

The technology center Eurecat, a Catalonia.health member, has incorporated a new technology called Olink® that analyzes up to 92 proteins simultaneously and accelerates the obtaining of results in advanced analysis of biological samples for the development of new products and services in sectors such as health, biotechnology, nutrition, and food.

The Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Nephrology Service of Hospital Germans Trias and the spin-off Debios Diagnostics, all three members of Catalonia.health, are driving the PROMORFI project, a translational innovation initiative aimed at improving the detection and monitoring of chronic kidney disease through new non-invasive diagnostic tools.

Nema Health, a biotechnology company specialized in personalized immunotherapies for cancer treatment and a Catalonia.health member, has closed its first seed funding round. The operation totals €1.06 million, comprising a capital increase of €730,000 and a grant of €335,000 awarded by the CDTI's NEOTEC program (2025 call).

D-Sight, a clinical-stage spin-off from the Vall d'Hebron Research Institute (VHIR) and a Catalonia.health member, has secured €2 million in a new funding round led by Clave Capital, the company's main investor, to accelerate its clinical development plan in neuroprotective therapies for ocular diseases.

Catalonia.health has formalized the renewal of its Board of Directors and appointed Eva García Ramos as the new president of the organization at the General Assembly held in L'Hospitalet de Llobregat.

The University of Barcelona, a Catalonia.health member, has presented the strategic project VISI-ON-BRAIN (Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders), a European training and research program with €4.5 million in funding that connects UB with the best research centers in Europe.

Zymvol, a biotechnology company and a member of Catalonia.health, has announced a strategic collaboration with Olon, a global CDMO and generic manufacturer, to accelerate the adoption of biocatalysis as a scalable manufacturing solution for the pharmaceutical industry.

Medichem Solutions S.L., a subsidiary of Medichem and a member of Catalonia.health, has announced a strategic collaboration with Breckenridge Pharmaceutical, Inc., a U.S.-based generic pharmaceutical company and subsidiary of Towa International.

Devicare, a leading pharmaceutical company in the field of urology and a member of Catalonia.health, has announced the acquisition of IP-6 International, Inc., a renowned North American nutritional supplement company and manufacturer of the IP6 Gold® brand. This operation represents Devicare's first acquisition outside Spain and constitutes a significant milestone in its international growth strategy.

The biotechnology company Orikine Bio, a member of Catalonia.health, has received €2.7 million in investment from SICC Innvierte of CDTI Innovación together with fund managers Asabys Partners (Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA) and AdBio Partners (AFB Seed Fund II), also members of Catalonia.health.

The Catalan ecosystem of emerging companies specialized in the health sector has achieved a new historic record in investment rounds. Funding raised through capital, grants and debt surged 60% year-on-year in 2025, reaching €378.2 million, with Catalonia.health member companies leading the main operations.

Asabys Partners, a venture capital firm based in Barcelona and a member of Catalonia.health, has announced the launch of Oriva Therapeutics, a company dedicated to developing innovative therapies in women's health. The new company has integrated two advanced assets from Oncostellae and Medibiofarma, targeting two chronic diseases with high unmet medical need: endometriosis and uterine fibroids.

Archivel Farma, a member of Catalonia.health, has announced the renewal of its GMP manufacturing certification, confirming compliance with the requirements of the new Annex 1 and Annex 2 to produce sterile, freeze-dried and biological products, in accordance with current European regulatory standards.

El passat 10 de febrer, catalonia.health va participar en la sessió "Explorant sinergies per a la salut global", una trobada de gran rellevància estratègica celebrada a ACCIÓ amb el Dr. Jarbas Barbosa da Silva Jr., director de la Pan American Health Organization (PAHO), l'organització que actua com a branca regional de la Organització Mundial de la Salut a l'hemisferi americà.

Els dies 8 i 9 de febrer, representants del sector biohealth català han participat en la segona edició delFIT4FUTURE Leaders Meeting celebrat a Bilbao, una trobada que ha reunit 14 territoris industrialsinnovadors d'Europa per definir el futur de la competitivitat industrial del continent.

Catalonia.health will participate in 4YFN 2026, the international event for startups and technology companies taking place from March 2 to 5 at Fira Gran Via in Barcelona, as part of the Mobile World Congress. 

The 12th edition brought together Catalonia's health ecosystem at the Gran Teatre del Liceu to celebrate innovation and the sector's collaborative spirit 

Barcelona, January 29, 2026 – Catalonia.health CEO Arantxa Sanz participated this week in the third edition of the "Life Sciences Innovation" conference series, co-organised with EY, which on this occasion explored the challenges and opportunities presented by the future regulation of medicines and medical products for the Spanish market.

HIPRA, a biotechnological company and member of Catalonia.health, and Elanco Animal Health have announced a strategic partnership to bring two vaccines against avian metapneumovirus (aMPV) to the United States poultry market.